Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... July 27, 2018 Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma January 19, 2024 Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... March 11, 2026 Load more HOT NEWS Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... Speaking a thousand words – how a cancer image collection is... Cauliflower Rice
